Cargando…

Evaluation of therapeutic effects of tetramethylpyrazine nitrone in Alzheimer’s disease mouse model and proteomics analysis

The pathophysiology of Alzheimer’s disease (AD) is multifactorial with characteristic extracellular accumulation of amyloid-beta (Aβ) and intraneuronal aggregation of hyperphosphorylated tau in the brain. Development of disease-modifying treatment for AD has been challenging. Recent studies suggest...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xinhua, Huang, Kaipeng, Wang, Yuqiang, Zhang, Zaijun, Liu, Yingying, Hou, Qinghua, Yang, Xifei, Hoi, Maggie Pui Man
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025301/
https://www.ncbi.nlm.nih.gov/pubmed/36950017
http://dx.doi.org/10.3389/fphar.2023.1082602
_version_ 1784909299122700288
author Zhou, Xinhua
Huang, Kaipeng
Wang, Yuqiang
Zhang, Zaijun
Liu, Yingying
Hou, Qinghua
Yang, Xifei
Hoi, Maggie Pui Man
author_facet Zhou, Xinhua
Huang, Kaipeng
Wang, Yuqiang
Zhang, Zaijun
Liu, Yingying
Hou, Qinghua
Yang, Xifei
Hoi, Maggie Pui Man
author_sort Zhou, Xinhua
collection PubMed
description The pathophysiology of Alzheimer’s disease (AD) is multifactorial with characteristic extracellular accumulation of amyloid-beta (Aβ) and intraneuronal aggregation of hyperphosphorylated tau in the brain. Development of disease-modifying treatment for AD has been challenging. Recent studies suggest that deleterious alterations in neurovascular cells happens in parallel with Aβ accumulation, inducing tau pathology and necroptosis. Therefore, therapies targeting cellular Aβ and tau pathologies may provide a more effective strategy of disease intervention. Tetramethylpyrazine nitrone (TBN) is a nitrone derivative of tetramethylpyrazine, an active ingredient from Ligusticum wallichii Franchat (Chuanxiong). We previously showed that TBN is a potent scavenger of free radicals with multi-targeted neuroprotective effects in rat and monkey models of ischemic stroke. The present study aimed to investigate the anti-AD properties of TBN. We employed AD-related cellular model (N2a/APPswe) and transgenic mouse model (3×Tg-AD mouse) for mechanistic and behavioral studies. Our results showed that TBN markedly improved cognitive functions and reduced Aβ and hyperphosphorylated tau levels in mouse model. Further investigation of the underlying mechanisms revealed that TBN promoted non-amyloidogenic processing pathway of amyloid precursor protein (APP) in N2a/APPswe in vitro. Moreover, TBN preserved synapses from dendritic spine loss and upregulated synaptic protein expressions in 3×Tg-AD mice. Proteomic analysis of 3×Tg-AD mouse hippocampal and cortical tissues showed that TBN induced neuroprotective effects through modulating mitophagy, MAPK and mTOR pathways. In particular, TBN significantly upregulated PINK1, a key protein for mitochondrial homeostasis, implicating PINK1 as a potential therapeutic target for AD. In summary, TBN improved cognitive functions in AD-related mouse model, inhibited Aβ production and tau hyperphosphorylation, and rescued synaptic loss and neuronal damage. Multiple mechanisms underlie the anti-AD effects of TBN including the modulation of APP processing, mTOR signaling and PINK1-related mitophagy.
format Online
Article
Text
id pubmed-10025301
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100253012023-03-21 Evaluation of therapeutic effects of tetramethylpyrazine nitrone in Alzheimer’s disease mouse model and proteomics analysis Zhou, Xinhua Huang, Kaipeng Wang, Yuqiang Zhang, Zaijun Liu, Yingying Hou, Qinghua Yang, Xifei Hoi, Maggie Pui Man Front Pharmacol Pharmacology The pathophysiology of Alzheimer’s disease (AD) is multifactorial with characteristic extracellular accumulation of amyloid-beta (Aβ) and intraneuronal aggregation of hyperphosphorylated tau in the brain. Development of disease-modifying treatment for AD has been challenging. Recent studies suggest that deleterious alterations in neurovascular cells happens in parallel with Aβ accumulation, inducing tau pathology and necroptosis. Therefore, therapies targeting cellular Aβ and tau pathologies may provide a more effective strategy of disease intervention. Tetramethylpyrazine nitrone (TBN) is a nitrone derivative of tetramethylpyrazine, an active ingredient from Ligusticum wallichii Franchat (Chuanxiong). We previously showed that TBN is a potent scavenger of free radicals with multi-targeted neuroprotective effects in rat and monkey models of ischemic stroke. The present study aimed to investigate the anti-AD properties of TBN. We employed AD-related cellular model (N2a/APPswe) and transgenic mouse model (3×Tg-AD mouse) for mechanistic and behavioral studies. Our results showed that TBN markedly improved cognitive functions and reduced Aβ and hyperphosphorylated tau levels in mouse model. Further investigation of the underlying mechanisms revealed that TBN promoted non-amyloidogenic processing pathway of amyloid precursor protein (APP) in N2a/APPswe in vitro. Moreover, TBN preserved synapses from dendritic spine loss and upregulated synaptic protein expressions in 3×Tg-AD mice. Proteomic analysis of 3×Tg-AD mouse hippocampal and cortical tissues showed that TBN induced neuroprotective effects through modulating mitophagy, MAPK and mTOR pathways. In particular, TBN significantly upregulated PINK1, a key protein for mitochondrial homeostasis, implicating PINK1 as a potential therapeutic target for AD. In summary, TBN improved cognitive functions in AD-related mouse model, inhibited Aβ production and tau hyperphosphorylation, and rescued synaptic loss and neuronal damage. Multiple mechanisms underlie the anti-AD effects of TBN including the modulation of APP processing, mTOR signaling and PINK1-related mitophagy. Frontiers Media S.A. 2023-03-06 /pmc/articles/PMC10025301/ /pubmed/36950017 http://dx.doi.org/10.3389/fphar.2023.1082602 Text en Copyright © 2023 Zhou, Huang, Wang, Zhang, Liu, Hou, Yang and Hoi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Zhou, Xinhua
Huang, Kaipeng
Wang, Yuqiang
Zhang, Zaijun
Liu, Yingying
Hou, Qinghua
Yang, Xifei
Hoi, Maggie Pui Man
Evaluation of therapeutic effects of tetramethylpyrazine nitrone in Alzheimer’s disease mouse model and proteomics analysis
title Evaluation of therapeutic effects of tetramethylpyrazine nitrone in Alzheimer’s disease mouse model and proteomics analysis
title_full Evaluation of therapeutic effects of tetramethylpyrazine nitrone in Alzheimer’s disease mouse model and proteomics analysis
title_fullStr Evaluation of therapeutic effects of tetramethylpyrazine nitrone in Alzheimer’s disease mouse model and proteomics analysis
title_full_unstemmed Evaluation of therapeutic effects of tetramethylpyrazine nitrone in Alzheimer’s disease mouse model and proteomics analysis
title_short Evaluation of therapeutic effects of tetramethylpyrazine nitrone in Alzheimer’s disease mouse model and proteomics analysis
title_sort evaluation of therapeutic effects of tetramethylpyrazine nitrone in alzheimer’s disease mouse model and proteomics analysis
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025301/
https://www.ncbi.nlm.nih.gov/pubmed/36950017
http://dx.doi.org/10.3389/fphar.2023.1082602
work_keys_str_mv AT zhouxinhua evaluationoftherapeuticeffectsoftetramethylpyrazinenitroneinalzheimersdiseasemousemodelandproteomicsanalysis
AT huangkaipeng evaluationoftherapeuticeffectsoftetramethylpyrazinenitroneinalzheimersdiseasemousemodelandproteomicsanalysis
AT wangyuqiang evaluationoftherapeuticeffectsoftetramethylpyrazinenitroneinalzheimersdiseasemousemodelandproteomicsanalysis
AT zhangzaijun evaluationoftherapeuticeffectsoftetramethylpyrazinenitroneinalzheimersdiseasemousemodelandproteomicsanalysis
AT liuyingying evaluationoftherapeuticeffectsoftetramethylpyrazinenitroneinalzheimersdiseasemousemodelandproteomicsanalysis
AT houqinghua evaluationoftherapeuticeffectsoftetramethylpyrazinenitroneinalzheimersdiseasemousemodelandproteomicsanalysis
AT yangxifei evaluationoftherapeuticeffectsoftetramethylpyrazinenitroneinalzheimersdiseasemousemodelandproteomicsanalysis
AT hoimaggiepuiman evaluationoftherapeuticeffectsoftetramethylpyrazinenitroneinalzheimersdiseasemousemodelandproteomicsanalysis